Metsera outlines $250M IPO plans as obesity biotech competition rises
Metsera, a well-funded biotech trying to angle toward the front of the obesity medicine pack, has proposed a $250 million IPO. That would be the … Sign up to read this article for free. Get free access to a limited number of articles, plus …